Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of ICOTYDE (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents 12+ who weigh ≥40 kg.
ICOTYDE is the first oral IL‑23 receptor peptide; Phase 3 data (2,500 patients) showed ~70% IGA 0/1 and 55% PASI 90 at Week 16 with adverse reaction rates within 1.1% of placebo through Week 16 and no new safety signals through Week 52.
Johnson & Johnson (NYSE:JNJ) presented Phase 1 Erda-iDRS data at EAU 2026 showing an 89% complete response rate in intermediate-risk non–muscle-invasive bladder cancer with a median complete-response duration of 18 months (95% CI, 14–25). Median recurrence-free survival in high-risk patients was 20 months.
Treatment met its primary safety endpoint, showed predominantly local adverse events, limited systemic exposure, and supports ongoing Phase 2 and Phase 3 MoonRISe studies.
Johnson & Johnson (NYSE: JNJ) announced U.S. FDA approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens for cataract surgery, cleared March 12, 2026. The lens preserves contrast sensitivity comparable to an aspheric monofocal IOL and reported 97% patient absence of very bothersome visual disturbances. TECNIS PureSee IOL will be available in the U.S. later in 2026 and expands JNJ’s TECNIS surgical vision portfolio, which has served nearly 500,000 eyes globally.
Johnson & Johnson (NYSE:JNJ) announced U.S. FDA approval of TECVAYLI plus DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy. The approval is based on Phase 3 MajesTEC-3 results showing large, statistically significant benefits in PFS and OS versus standard regimens.
Key results: PFS hazard ratio 0.17 (83% risk reduction), three-year PFS 83% vs 30%; OS hazard ratio 0.46, three-year OS 83.3% vs 65.0%. Safety signals include high infection rates and cytokine release syndrome that was mainly Grade 1/2.
Johnson & Johnson (NYSE: JNJ) announced that nipocalimab received U.S. FDA Fast Track designation for adults with systemic lupus erythematosus (SLE) on March 3, 2026. The designation recognizes unmet need and may expedite development and review timelines.
Nipocalimab showed reduced lupus disease activity and potential steroid-sparing in a Phase 2 study (JASMINE), and Johnson & Johnson is enrolling adults in the Phase 3 GARDENIA study.
Johnson & Johnson (NYSE: JNJ) said nipocalimab received U.S. FDA Fast Track designation for adults with systemic lupus erythematosus (SLE) on March 3, 2026. The designation reflects unmet need and may accelerate review. A Phase 2b (JASMINE) showed reduced lupus disease activity and steroid-sparing potential; Phase 3 (GARDENIA) enrollment is underway.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call to discuss first-quarter results at 8:30 a.m. ET on Tuesday, April 14, 2026. Joaquin Duato, CEO; Joseph Wolk, CFO; and Darren Snellgrove, VP Investor Relations, will host and additional executives will join the Q&A.
The webcast and presentation materials will be available at www.investor.jnj.com. A replay will be posted about three hours after the call and remain available until approximately 12:00 a.m. on April 28, 2026. U.S. dial-in numbers and international numbers are provided for live participation and replay; the replay conference ID is 13759017. The press release will be available at about 6:45 a.m. ET on the morning of the call.
Johnson & Johnson (NYSE:JNJ) reported preliminary Phase 1b results showing the bispecific T-cell engager pasritamig plus docetaxel produced deep, durable PSA reductions and a safety profile consistent with docetaxel alone. Among 51 patients, PSA declines ≥50% occurred in 64.7% overall and 75.0% of taxane-naïve patients. No cytokine release syndrome or treatment-related deaths were observed. The program is advancing into Phase 3 studies, with two trials ongoing and regulatory designations in China and the U.S.
Johnson & Johnson (NYSE: JNJ) submitted an sBLA to the FDA on Feb 24, 2026, seeking approval of IMAAVY (nipocalimab) as the first treatment for warm autoimmune hemolytic anemia (wAIHA).
Phase 2/3 ENERGY showed a rapid, durable hemoglobin response and improved fatigue versus placebo; IMAAVY was generally well tolerated. Full ENERGY results are forthcoming.
Johnson & Johnson (NYSE: JNJ) reported long-term QUASAR LTE results showing sustained TREMFYA (guselkumab) benefit through Week 140 in adults with moderately to severely active ulcerative colitis. At Week 140, 80.8% were in clinical remission, 78.6% achieved histo-endoscopic mucosal improvement, and 53.6% reached endoscopic remission.
About 89% of eligible participants completed treatment through Week 140, 87.5% of Week 44 remitters stayed in remission through Week 140, efficacy held regardless of prior biologic/JAK history, and no new safety concerns were observed.